IsoRay (ISR)
IsoRay Revenues: 1.229M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ISR Revenues Rankings
| Overall | 2nd percentile | 4310 of 4432 |
| Sector | 12th percentile | 411 of 470 in Healthcare |
| Industry | 8th percentile | 61 of 67 in Medical Instruments & Supplies |
ISR Revenues Range, Past 5 Years
| Minimum | 1.203M | Mar 2010 |
| Maximum | 1.856M | Sep 2007 |
| Average | 1.432M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these ISR related companies
ISR News
$isr flagging intraday might get some juice over 1.4 or so http://stks.co/41yi
about an hour ago by kunal00
about an hour ago by kunal00
$ISR - this stock just formed an intra-day b/o and fully expect to gap up like $MVIS and run tomorrow morning. Wouldnt long either now
about 14 hours ago by onstocks
about 14 hours ago by onstocks
$ISR looking strong on nice news today and was also on Discovery Channel
about a day ago by taraprofitt
about a day ago by taraprofitt
$ISR nice press this morning technology featured on The Discovery Channel.
about a day ago by taraprofitt
about a day ago by taraprofitt
IsoRay's Cesium-131 Prostate Cancer Treatment Featured on Discovery Channel
May 29, 7:50AM Marketwire
May 29, 7:50AM Marketwire
$ISR interesting company with news news out this morning. Very promising products coming to market soon
about 8 days ago by taraprofitt
about 8 days ago by taraprofitt
IsoRay (ISR) Says GliaSite System Received CE Mark; to Go On Sale in 31 European Markets
May 22, 8:17AM Street Insider
May 22, 8:17AM Street Insider
IsoRay to Introduce GliaSite and Cesium-131 Mesh to International Audience at World Congress of Brachytherapy
May 07, 7:55AM Business Wire
May 07, 7:55AM Business Wire
IsoRay to Demonstrate GliaSite at Annual Meeting of American Association of Neurological Surgeons
Apr 10, 7:53AM Business Wire
Apr 10, 7:53AM Business Wire
IsoRay Applauds Cleveland Clinic Prostate Study Conclusions on Brachytherapy Superiority
Feb 07, 8:07AM Business Wire
Feb 07, 8:07AM Business Wire
$ISR filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/1rb7
about 141 days ago by MarketBrief
about 141 days ago by MarketBrief
IsoRay, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Dec 05, 10:08AM PR Newswire
Dec 05, 10:08AM PR Newswire
WestPark Capital, Inc., WestPark Capital, Announces $2.6 Million IsoRay Offering
Dec 02, 8:32PM PR Newswire
Dec 02, 8:32PM PR Newswire
IsoRay, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
Nov 29, 10:08AM PR Newswire
Nov 29, 10:08AM PR Newswire
IsoRay receives final regulatory approval for GliaSite brain cancer treatmen
Nov 22, 7:48AM FlyOnTheWall
Nov 22, 7:48AM FlyOnTheWall
IsoRay Receives Final Regulatory Approval for GliaSite Brain Cancer Treatment
Nov 22, 7:47AM Benzinga
Nov 22, 7:47AM Benzinga
IsoRay Receives Final Regulatory Approval for GliaSite® Brain Cancer Treatment
Nov 22, 7:47AM Business Wire
Nov 22, 7:47AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ISR | 1.25 | +0.08 | +6.84% | 34.30M |
| ISNS | 5.17 | -0.14 | -2.64% | 25.38M |
| ISLE | 5.18 | -0.14 | -2.63% | 207.37M |
| ISL | 12.44 | +0.01 | +0.08% | |
| ISIS | 10.08 | +0.17 | +1.72% | 992.59M |
| ISIL | 10.66 | -0.18 | -1.66% | 1.372B |
| IOSP | 26.49 | -0.82 | -3.00% | 630.04M |
| IOO | 56.80 | -1.04 | -1.80% | |
| IO | 6.03 | -0.36 | -5.63% | 994.22M |
| INXN | 16.85 | -0.51 | -2.94% | 1.148B |
